Skip to main content

Eli Lilly and Company(LLY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low881.11
Day High913.05
Open:910.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes made by Lilly at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey
the globe and mail

Public health plans should cover Mounjaro for Type 2 diabetes, Canada’s Drug Agency recommends

Non-binding recommendation made on condition that Eli Lilly offer the drug at a discount
Tipranks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arrowhead Pharmaceuticals (ARWR)
Motley Fool
Why Did Eli Lilly Stock Drop Today?
Motley Fool
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Motley Fool
Why Legend Biotech Stock Crushed the Market on Monday
MarketBeat
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%
MarketBeat.com
Motley Fool
Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?
StockStory
Eli Lilly (LLY): 3 Reasons We Love This Stock
LLY
Tipranks
Eli Lilly’s Oral Orforglipron Study Completion Signals Next Step in Diabetes and Obesity Market Race
Tipranks
Lilly’s New Autoimmune Candidate LY4298445 Moves Through Early Testing
Motley Fool
2 Millionaire-Maker Stocks to Hold for the Next 10 Years
Motley Fool
This Drug Stock Has Crushed the S&P 500 Over the Last Decade
Tipranks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atai Beckley N.V. (ATAI)
Tipranks
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV), Decibel Cannabis Company (OtherDBCCF) and Eli Lilly & Co (LLY)
Tipranks
Scotiabank Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
Tipranks
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Eli Lilly & Co (LLY) and Ionis Pharmaceuticals (IONS)
Motley Fool
Better Long-Term Buy: Eli Lilly or Viking Therapeutics?
Motley Fool
Is This the Biggest Game-Changer in Lilly's 150-Year History?
Zacks Investment Research
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
MarketBeat
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
MarketBeat.com
Motley Fool
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?
Motley Fool
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
Motley Fool
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
Motley Fool
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
Tipranks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR)
Tipranks
Eli Lilly & Co (LLY) Receives a Buy from Morgan Stanley
Motley Fool
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
Motley Fool
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
Motley Fool
Worried About a Stock Market Crash? These 3 Stocks Beat the S&P 500 by Wide Margins When It Nosedived in 2022, and They Could Do It Again
Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
Tipranks
Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Omada Health, Inc. (OMDA) and Eli Lilly & Co (LLY)
Motley Fool
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?

Profile

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.